Enrolling by Invitation
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
NCT06549400
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +9 more
- Locations
-
- Laboratory for Muscle Diseases and Neuropathies Leuven, Belgium
- Aarhus University Hospital Aarhus, Denmark
- Ludug-Maximilians University München, Germany
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata Rome, Italy